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A B S T R A C T
The aim of this study was to examine the quality of life (QoL) in 40 Croatian metastatic melanoma patients who had
completed at least first-line treatment and to see if there was a correlation between QoL parameters and serum lactate
dehydrogenase (LDH). LDH levels were measured and all patients clinically examined between April and September
2013. Two QoL questionnaires were used for patient self-evaluation: the European Organization for Research and Treat-
ment of Cancer Quality of life Questionnaire (EORTC QLQ-C30) and the Dartmouth Primary Care Cooperative Re-
search Network and the World Organization of National Colleges, Academies, and Academic Associations of General
Practitioners/Family Physicians (COOP/WONCA) charts. The average EORTC QLQ-C30 score for global health status
(GHS) was 41.204. The average scores for functional scales were high, with the exception of emotional functioning
(65.02). Blood LDH levels positively correlated with the Eastern Cooperative Oncology Group (ECOG) status (r=0.415;
p<0.01) and pain (r=0.345; p<0.05), but not with any functional or COOP/WONCA scores. Global health status (GHS)
positively correlated with patient age at the time of evaluation (r=0.386; p<0.05) and age at the time when metastatic
disease had been diagnosed (r=0.366; p<0.05). Quality of life for the studied group of metastatic melanoma patients in
Croatia can be considered generally good, with the exception of emotional functioning and symptoms of fatigue, disp-
noea, insomnia, and financial difficulties.
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Introduction
In oncology patients, quality of life (QoL) is often af-
fected as soon as patients become aware of their disease
and of the limited therapeutic resources at hand, and yet
QoL in these patients is understudied, especially in met-
astatic melanoma patients. It is only over the last ten
years that therapy research has included QoL for pati-
ents with cancer at an advanced stage, including mela-
noma1–5, most often using standardised and sometimes
disease-specific questionnaires6.
Regardless of greater awareness about the risk fac-
tors and new therapy options, melanoma incidence and
mortality has been rising worldwide. In Croatia, total
melanoma incidence has increased 149% in men and
130% in women from 1998 to 2008, whereas mortality
has increased 45% in men and 50% in women7.
For more than a decade, dacarbazine (DTIC) and
temozolomide had been the only approved metastatic
melanoma therapies, with limited effects on disease con-
trol. Current chemotherapy of metastatic melanoma may
also include vinca alkaloids, nitrosourea, platinum-based
compounds, and taxanes alone or more often in combina-
tion with DTIC or temozolomide. Over the last ten years,
clinical trials have focused on immunomodulators such
as interleukin 2 (IL-2) and interferon alpha (IFN a), but
the greatest breakthrough in treating metastatic mela-
noma has come with targeted biological therapy, above
all with BRAF and MEK inhibitors and then with anti
CTLA-4 and PD-1/PD-L1 monoclonal antibodies8–11.
These new therapies have increased the survival in meta-
static melanoma patients but have also affected their
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QoL, as they are associated with a number of adverse ef-
fects that interfere with everyday patient activities9,11. In
addition, these new therapies are very expensive and
none has been included in the list of medicinal products
for the treatment of metastatic melanoma that are cov-
ered by the Croatian Health Insurance Fund (CHIF)12–14.
Considering the current state of Croatian economy, aver-
age income, and the unemployment rate, a large number
of metastatic melanoma patients cannot afford this kind
of treatment15,16.
As the disease progresses the tumour becomes larger,
and its vessels become insufficient to supply the tumour
with blood. This leads to necrosis within the tumour and
the levels of blood lactate dehydrogenase (LDH) rise17,18.
The aim of this study was to establish QoL in Croatian
metastatic melanoma patients who had completed first-
-line therapy and to test our assumption that high LDH
levels as an indicator of advanced disease should in-
versely correlate with QoL. We also wanted to see if
serum LDH correlated with any of the functional scales
and global health status (GHS) and whether QoL dif-
fered between genders and therapies received so far.
Patients and methods
This study was approved by the Ethics Committee of
the Clinical Hospital »Sestre milosrdnice«, and all pati-
ents gave their informed consent before entering the
study. The study included 40 adult patients treated at the
Oncology and Nuclear Medicine Clinic of the Clinical
Hospital »Sestre milosrdnice« from April to September
2013. All patients had previously been diagnosed meta-
static melanoma according to the American Joint Com-
mittee on Cancer (AJCC) melanoma staging guidelines19,
had received at least one treatment cycle, and had regu-
larly been followed up.
Another inclusion criterion was the Eastern Coopera-
tive Oncology Group (ECOG) Performance Status be-
tween 0 and 2, where grade »0« stands for a fully active
patient who is able to carry out all daily activities as
before the disease developed and grade »2« for an ambu-
latory patient, who is up and about more than 50% of the
waking time and capable of all self-care, but unable to
perform work activities20. We opted for this inclusion
criterion to be able to compare our findings with most
QoL studies in oncology patients published so far4,5.
For correlation analysis we took serum LDH values
from the most recent measurements.
Of the 40 study patients, 15 were men and 25 women.
Table 1 shows patient demographics. Twenty-five had
the ECOG grade 0, thirteen grade 1, and two grade 2. At
diagnosis, their mean age was 50.67±15.70 years, rang-
ing from 21 to 76 years. On study enrolment, their mean
age was 58.03±14.27 years, ranging from 26 to 79 years.
Average time between the first diagnosis of metastatic
melanoma and study enrolment/QoL measurement was
8.62 years.
For QoL evaluation the patients were asked to com-
plete two self-administered questionnaires: the trans-
lated Croatian version 3.0 of the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire C30 (EORTC QLQ-C30)6,21–24 and the
Dartmouth Primary Care Cooperative Research Net-
work and the World Organization of National Colleges,
Academies, and Academic Associations of General Prac-
titioners/Family Physicians (COOP/WONCA) question-
naire25–27. The EORTC QLQ-C30 consisted of five func-
tional scales (physical, role, cognitive, emotional, and
social) in which higher score indicates higher functional-
ity, three symptom scales (nausea/vomiting, pain, and fa-
tigue) and six single items (dyspnoea, insomnia, appetite
loss, constipation, diarrhoea, and financial difficulties) in
which higher score indicates serious symptoms, and fi-
nally a global health status (GHS)/QoL scale, in which
higher score indicates better quality of life6,21–24. The
COOP/WONCA questionnaire consisted of six charts, five
of which served to evaluate patient’s state, including
physical fitness, feelings (which include fear, anxiety and
pain), daily activities, social activities, and overall health,
whereas the sixth chart evaluated change in health.
Items were scored on a five-point Likert scale, where »1«
indicated no impairment and »5« the worst impairment.
All score descriptors were accompanied by illustrati-
ons25–27. The use of the two questionnaires was approved
by respective copyright owners.
The questionnaires were distributed to patients by
study doctors during scheduled visits and were com-
pleted before diagnostic or therapeutic procedures and
counselling about disease progress and further therapy.
To the best of our knowledge, this study is the first to
combine the two questionnaires to evaluate QoL in pati-
ents with metastatic melanoma.
Statistical analysis
All data were analysed using the SPSS package ver-
sion 18.0. Due to a small sample, non-normal distribu-
tion of data, and a great number of ordinal-type variables
(all COOP/WONCA scales and the EORTC QLQ-C30
symptom scales), we used medians and the non-paramet-
ric Mann-Whitney U test for differences between two
independent samples, Kruskal-Wallis test for differences
between several independent samples, and Spearman’s
rank correlation coefficient. Statistical significance was
set at p<0.05 and p<0.01 for all tests.
Results
Most (28) patients received DTIC, whereas seven pati-
ents received Vemurafenib and five other treatment (Ta-
ble 1).
Mean serum LDH was 293.27±172.49 U/L (at 37 °C),
ranging from 130 to 1003 U/L (at 37 °C), whereas the
normal range for adults over 20 years of age is<241 U/L
(37 °C). High serum LDH was found in 15 patients.
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Of the 40 patients in the study, 37 completed the
EORTC QLQ-C30 questionnaire, whereas three failed to
answer at least one question. The questionnaires of these
three patients were included in the final data analysis. In
most functional scales the patients showed high scores,
except for the feelings, which points to a higher degree of
tension and worry among them (Table 2).
The scores on the symptom scales suggest good con-
trol over the symptoms usually associated with meta-
static diseases; only fatigue, dyspnoea, and insomnia
affected patient performance to a higher degree, whereas
pain affected it moderately.
Financial difficulties also seem to have significantly
affected patient performance (Table 2).
On the scale between 1 (very poor) and 7 (excellent),
the patients rated their GHS with the median score 4. On
the same scale range from 1 to 7, the median score for
QoL was 4, which was also the most common score
among the patients (mode). These results indicate that
the patients’ quality of life and health status had dimin-
ished.
The correlations between functional scales (Table 3)
show significantly inverse correlation between GHS and
feelings, cognitive, social, physical, and role function.
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EORTC QLQ C30 FINDINGS BY SCALES
Q1 Median Q3
GHS 21.528 41.204 56.250
Functional scales
Physical 68.333 86.667 93.333
Role 66.667 71.272 100.000
Emotional 43.750 65.019 83.333
Cognitive 66.667 83.333 100.000
Social 66.667 83.333 100.000
Symptom scales
Fatigue 22.222 33.333 61.111
Nausea/vomiting 0.000 0.000 16.667
Pain 0.000 16.667 33.333
Dyspnoea 0.000 33.333 33.333
Insomnia 0.000 31.624 66.667
Loss of appetite 0.000 0.000 33.333
Constipation 0.000 0.000 33.333
Diarrhoea 0.000 0.000 8.333
Financial difficulties 0.000 26.852 58.333
GHS – global health status
TABLE 3
CORRELATIONS BETWEEN FUNCTIONAL SCALES (EORTC QLQ C-30)
GHS FF FU EF KF SF
GHS 1.000 –0.468** –0.450** –0.371** –0.448** –0.382*
Physical 1.000 0.651** 0.432* 0.471** 0.689**
Role 1.000 0.675* 0.518** 0.701**
Emotional 1.000 0.695** 0.606**
Cognitive 1.000 0.524**
Social 1.000
*p<0.05 (two-way), ** p<0.01 (two-way); GHS – global health status
The correlation between other functions was positive
and significant.
We also observed a significant correlation between
patient age at questionnaire completion and GHS and a
significant inverse correlation between age and physical
function. In other words, the patients found that their
health status improved, yet their perception of their
physical condition got worse with age. Furthermore,
patients who had longer been diagnosed metastatic mela-
noma found their health status better than those who
had learned of their diagnoses more recently.
Looking at the symptoms, older patients reported fatigue
and constipation more often, whereas high blood LDH
was associated with more frequent nausea and vomiting.
Patients with higher ECOG grade rated their physical
and role function lower, reported nausea/vomiting, in-
somnia, and loss of appetite more often, and had higher
blood LDH (Table 4).
Greater fatigue correlated with most of the reported
symptoms (nausea/vomiting, pain, dyspnoea, insomnia,
loss of appetite, constipation) but not with diarrhoea and
financial difficulties (Table 5).
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TABLE 4
CORRELATIONS BETWEEN CLINICAL DATA, DEMOGRAPHICS, FUNCTIONAL SCALES, AND SYMPTOMS (EORTC QLQ C-30)
Age at diagnosis of
metastatic melanoma
ECOG status Age at evaluation
Last measured blood
LDH (U/L)
GHS 0.366* 0.207 0.386* 0.245
Physical –0.202 –0.354* –0.346* –0.100
Role –0.243 –0.363* –0.273 –0.259
Emotional –0.080 –0.214 –0.065 –0.207
Cognitive 0.012 –0.185 –0.132 0.108
Social –0.158 –0.309 –0.19 –0.307
Fatigue 0.197 0.414** 0.368* 0.207
Nausea/vomiting –0.01 0.319* –0.07 0.47**
Pain 0.069 0.234 0.177 0.225
Dyspnoea 0.189 0.286 0.3 0.165
Insomnia 0.081 0.468* 0.222 0.03
Loss of appetite 0.168 0.532** 0.189 0.282
Constipation 0.159 0.079 0.325* 0.210
Diarrhoea –0.071 –0.109 –0.021 –0.035
Financial difficulties 0.065 0.181 0.075 0.035
Last measured blood LDH (U/L) 0.148 0.415** 0.035 1
*p<0.05 (two-way), ** p<0.01 (two-way)
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Pain 0.596** 0.396* 1
Dyspnoea 0.642** 0.147 0.566** 1
Insomnia 0.573** 0.397* 0.411** 0.374* 1
Loss of appetite 0.466** 0.622** 0.446** 0.221 0.293 1
Constipation 0.281 0.016 0.39* 0.05 0.202 0.043 1
Diarrhoea 0.296 0.031 0.233 0.249 0.163 –0.055 0.238 1
Financial difficulties 0.287 –0.040 0.550** 0.566** 0.271 0.154 0.166 0.151 1
GHS 0.572** 0.265* 0.353* 0.362* 0.416** 0.138 0.444** 0.190 0.233
*p<0.05 (two-way), ** p<0.01 (two-way)
GHS – global health status
Greater pain was also significantly associated with
other symptoms (except for diarrhoea).
Interestingly, dyspnoea was most often reported by
patients who rated high their financial difficulties, as
well as by patients reporting fatigue and diarrhoea.
Low rating of GHS was significantly associated with
higher scores for fatigue, pain, dyspnoea, insomnia, and
constipation (Table 5).
Similar to the EORTC QLQ-C30 findings, the analy-
sis of the COOP/WONCA charts shows a significant
correlation between the intensity of pain and LDH levels.
The patients reported better health status as the
pain, anxiety and fear lessened, and their social activities
intensified. The same is true if their rating of the change
in health was lower.
The charts have also confirmed the significant associ-
ation between patient age and health status rating estab-
lished by the EORTC QLQ-C30. Good health status was
also associated with lower ECOG grade and higher rating
of social activity. Patients who reported intense feelings
of anxiety, fear, and uncertainty also reported increased
pain and lower social and daily activity. Daily activity
significantly correlated with social activity and dropped
with the rating of pain (Table 6).
We did not establish any differences in any of the QoL
variables between genders or treatment groups regard-
less of the questionnaire (data not shown).
Discussion and conclusion
Our study has confirmed earlier findings that QoL
diminishes in patients with metastatic melanoma. In our
patient group, this was most prominent in the emotional
aspect, which does not come as a surprise, considering
that Croatian hospitals have not developed a system of
psychological support for their oncology patients. Kas-
parian28 reported that 30% of melanoma patients suf-
fered from one or other form of psychological disorder
that required psychological support and treatment. Cor-
nish et al.29 found that, similar to our study, psychologi-
cal disorders were common in patients in the follow-up
stage, whereas patients receiving chemotherapy and/or
intereferon reported lower role, emotional, social, and
cognitive function and poorer GHS.
In our study, better general health score was associ-
ated with older age. Blood LDH did not seem to affect it,
but higher ECOG grade and the intensity of pain did.
LDH showed a strong correlation with nausea/vomiting,
pain, and ECOG grade. Our findings are in line with
what has already been reported on QoL in patients with
metastatic melanoma30 and call for setting up systematic
psychological/psychiatric support for oncology patients,
melanoma patients in particular1–4,28. We also believe
that our findings may provide some direction for sup-
portive and paliative therapy. This primarily refers to
pain relief in the form of pharmacological and radiother-
apy as well as acupuncture31–34. Improvements are also
possible in the treatment and prevention of nausea and
vomiting with a variety of medicinal products available
to that end.
We also believe that new therapy options such as
BRAF and MEK inhibitors and monoclonal antibodies
may improve patient QoL, but in Croatia right now the
number of patients receiving this novel type of treatment
is quite limited, and only future studies will be able to
compare current and novel treatment and investigate
how financial status affects QoL in patients with meta-
static melanoma in this country.
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Age at diagnosis –0.073 0.069 0.175 0.248 0.129 0.221 0.226
ECOG status 0.050 0.018 0.247 0.371* 0.190 0.243 0.020
Age at evaluation 0.034 0.079 0.215 0.270 0.018 0.345* 0.232
Last measured blood LDH (U/L) 0.011 –0.087 0.218 0.248 0.356* 0.155 0.180
Physical fitness 1.000 –0.087 –0.088 0.089 0.023 –0.011 0.255
Feelings 1.000 0.757** 0.650** 0.469** 0.563** 0.261
Daily activities 1.000 0.768** 0.579** 0.556** 0.010
Social activities 1.000 0.532** 0.698** 0.175
Pain 1.000 0.425** –0.001
Overall health 1.000 0.339*
Change in health 1.000
*p<0.05 (two-way), **p<0.01 (two-way)
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KVALITETA @IVOTA BOLESNIKA SA METASTATSKIM MELANOMOM U HRVATSKOJ
S A @ E T A K
Cilj ovoga istra`ivanja je bio ispitati kvalitetu `ivota i njenu povezanost sa razinama laktat dehidrogenaze (LDH) u
krvi bolesnika te utvrditi povezanost vrijednosti LDH i pojedinih skala upitnika kvalitete `ivota. U razdoblju od travnja
do rujna 2013. u ovo istra`ivanje je uklju~eno ~etrdeset bolesnika sa ranije dijagnosticiranim metastatskim melanomom
koji su zavr{ili barem jednu liniju lije~enja i nalaze se u periodu pra}enja bolesti. Svi su bolesnici klini~ki pregledani i
svoma su izmjerene vrijednosti LDH u krvi. Za samoprocjenu kvalitete `ivota bolesnika su kori{tena dva upitnika: Eu-
ropean Organization for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-C30) i Dart-
mouth Primary Care Cooperative Research Network (COOP) and the World Organization of National Colleges, Acade-
mies, and Academic Associations of General Practitioners/Family Physicians (WONCA) score (COOP/WONCA). Re-
zultat ukupne procjene zdravstvenog stanja (GHS) EORTC QLQ-C30 upitnika je 41,203, rezultati funkcionalnih ljest-
vica su bili visoki uz isuzetak emotvne skale funkcionalnosti (65,02). Razine LDH u krvi su povezane sa ECOG (Eastern
Cooperative Oncology Group) statusom bolesnika (r=0,415 p<0,01) i ja~inom boli (r=0,345; p<0,05), no nema poveza-
nosti sa niti jednom skalom funkcionalnosti COOP WONCA upitnika. Bolesnici svoje zdravlje procjenjuju boljim sa
ve}om dobi kod postavljanja dijagnoze metastatskog melanoma i ispunjavanja upitnika. (r=0,366; p<0,05). Kvaliteta
`ivota ispitivane skupine bolesnika sa metastatskim melanomom je smanjena a posebno je sni`ena emotivna funk-
cionalnost te su ja~e izra`eni simptomi umora, zaduhe, nesanice i financijske pote{ko}e.
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